Our signature service.

You need this when

You are evaluating a specific molecule, route, or platform — in-licensing, acquisition, or investment — and you need to know whether it holds up industrially before you commit capital.

Or: you own the asset, and you want to find the problems before your counterparty does.

The question this answers

Clinical diligence tells you whether a molecule works. Commercial diligence tells you whether anyone will pay for it. Neither tells you whether it can be manufactured at a cost that makes the business case survive.

That gap is where deals quietly fail.

What you get

1. Route assessment. The current synthetic or manufacturing route, evaluated for scalability. Which steps break at scale, and why.

2. Alternative routes where relevant. If the incumbent route is the constraint, we assess whether better ones exist — with the same rigour we apply in competitive synthesis-design work.

3. Indicative COGS. A defensible cost-of-goods estimate at commercial scale, with the assumptions stated explicitly so you can challenge them.

4. Hidden risk register. Reagent availability, hazardous or regulated steps, CDMO willingness, IP constraints on the route, single-source dependencies, process safety exposure.

5. Go / no-go verdict. A stated position, with the reasoning. Not a menu of considerations — a conclusion you can take into an investment committee.

Format

• Duration: 3–4 weeks
• Deliverable: written review + verdict + live debrief
• Investment: from € 25,000

Why this is credible

This is not a desk exercise. It draws on a Ph.D. in organic and medicinal chemistry, direct CMC/GMP development experience, CDMO contract management, and competitively awarded work designing GMP-compatible synthetic routes against explicit COGS targets.

We have built full route portfolios — Peterson olefination, HWE, and Pd-coupling strategies compared head to head with costed COGS tables — for exactly this kind of decision.